CN104130302B - 一种核苷药物的晶型及其制备方法 - Google Patents
一种核苷药物的晶型及其制备方法 Download PDFInfo
- Publication number
- CN104130302B CN104130302B CN201410391177.9A CN201410391177A CN104130302B CN 104130302 B CN104130302 B CN 104130302B CN 201410391177 A CN201410391177 A CN 201410391177A CN 104130302 B CN104130302 B CN 104130302B
- Authority
- CN
- China
- Prior art keywords
- crystal formation
- crystal
- suo feibuwei
- solvent
- peak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 101
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 239000003814 drug Substances 0.000 title description 16
- 229940079593 drug Drugs 0.000 title description 4
- 239000002773 nucleotide Substances 0.000 title description 3
- 125000003729 nucleotide group Chemical group 0.000 title description 3
- 239000002904 solvent Substances 0.000 claims abstract description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 13
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 80
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 31
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 19
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 18
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical group CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- -1 hexamethylene Alkane Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 8
- 229960002063 sofosbuvir Drugs 0.000 abstract description 3
- TTZHDVOVKQGIBA-IQWMDFIBSA-N sofosbuvir Chemical compound N1([C@@H]2O[C@@H]([C@H]([C@]2(F)C)O)CO[P@@](=O)(N[C@@H](C)C(=O)OC(C)C)OC=2C=CC=CC=2)C=CC(=O)NC1=O TTZHDVOVKQGIBA-IQWMDFIBSA-N 0.000 abstract description 3
- 239000012296 anti-solvent Substances 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 238000005755 formation reaction Methods 0.000 description 69
- 239000007787 solid Substances 0.000 description 29
- 238000001514 detection method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000001757 thermogravimetry curve Methods 0.000 description 8
- 208000005176 Hepatitis C Diseases 0.000 description 7
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 229910017488 Cu K Inorganic materials 0.000 description 1
- 229910017541 Cu-K Inorganic materials 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000004164 analytical calibration Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Abstract
Description
温度 | 晶型 | 溶解度 |
25℃ | 晶型6 | 1.58mg/mL |
25℃ | 晶型A | 2.15mg/mL |
37℃ | 晶型6 | 2.37mg/mL |
37℃ | 晶型A | 3.03mg/mL |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410391177.9A CN104130302B (zh) | 2014-08-08 | 2014-08-08 | 一种核苷药物的晶型及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410391177.9A CN104130302B (zh) | 2014-08-08 | 2014-08-08 | 一种核苷药物的晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104130302A CN104130302A (zh) | 2014-11-05 |
CN104130302B true CN104130302B (zh) | 2017-02-15 |
Family
ID=51803193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410391177.9A Active CN104130302B (zh) | 2014-08-08 | 2014-08-08 | 一种核苷药物的晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104130302B (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3845221B1 (en) | 2014-06-13 | 2023-12-13 | Ratiopharm GmbH | Solid state forms of sofosbuvir |
WO2016023906A1 (en) * | 2014-08-13 | 2016-02-18 | Sandoz Ag | A crystalline form of sofosbuvir |
CN104974205A (zh) * | 2014-09-19 | 2015-10-14 | 苏州晶云药物科技有限公司 | 索非布韦的晶型a及其制备方法 |
CN104447924B (zh) * | 2014-11-07 | 2016-09-28 | 南京旗昌医药科技有限公司 | 索氟布韦的晶型及其制备方法 |
CN105732751A (zh) * | 2014-12-09 | 2016-07-06 | 北京万生药业有限责任公司 | 索非布韦新晶体 |
WO2016097173A1 (en) * | 2014-12-17 | 2016-06-23 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
CN105801645B (zh) * | 2014-12-29 | 2019-01-04 | 浙江海正药业股份有限公司 | 制备索非布韦晶型6的方法 |
EP3256104A1 (en) * | 2015-02-13 | 2017-12-20 | Sandoz AG | Pharmaceutical compositions comprising ledipasvir and sofosbuvir |
CN105985394B (zh) * | 2015-02-26 | 2020-09-22 | 石药集团中奇制药技术(石家庄)有限公司 | 一种索非布韦新晶型及其制备方法 |
WO2016156512A1 (en) | 2015-04-01 | 2016-10-06 | Sandoz Ag | A process for preparing a crystalline form of sofosbuvir |
CN106146589B (zh) * | 2015-04-10 | 2019-03-05 | 正大天晴药业集团股份有限公司 | 氘代核苷衍生物的结晶 |
CN104804054B (zh) * | 2015-04-17 | 2017-10-24 | 南京旗昌医药科技有限公司 | 一种索氟布韦的晶型及其应用 |
CN105017359A (zh) * | 2015-07-08 | 2015-11-04 | 苏州晶云药物科技有限公司 | 一种索非布韦晶型的制备方法 |
WO2017029408A1 (en) | 2015-08-20 | 2017-02-23 | Ratiopharm Gmbh | Solid state forms of sofosbuvir |
CN108084237A (zh) * | 2016-11-23 | 2018-05-29 | 广东东阳光药业有限公司 | 索非布韦的一水合物及其制备方法 |
CN108659077A (zh) * | 2017-03-27 | 2018-10-16 | 四川科伦博泰生物医药股份有限公司 | 核苷磷酰胺类化合物的晶型及制法、用途、衍生组合物 |
EP3661944A1 (en) | 2017-08-03 | 2020-06-10 | Sandoz AG | Sofosbuvir hydrate |
CN109467577A (zh) * | 2018-12-06 | 2019-03-15 | 南通常佑药业科技有限公司 | 一种索非布韦晶型及无定型产品的制备方法 |
CN109517018B (zh) * | 2018-12-29 | 2021-05-04 | 石药集团中奇制药技术(石家庄)有限公司 | 一种索磷布韦新晶型及其制备方法 |
WO2021203409A1 (zh) * | 2020-04-10 | 2021-10-14 | 南京正大天晴制药有限公司 | 一种用于治疗丙肝的无引湿性低变异性新晶型 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI576352B (zh) * | 2009-05-20 | 2017-04-01 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
AU2011235044A1 (en) * | 2010-03-31 | 2012-11-22 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
KR102108864B1 (ko) * | 2010-07-19 | 2020-05-12 | 길리애드 사이언시즈, 인코포레이티드 | 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법 |
US8871737B2 (en) * | 2010-09-22 | 2014-10-28 | Alios Biopharma, Inc. | Substituted nucleotide analogs |
CA2840242C (en) * | 2011-09-16 | 2019-03-26 | Gilead Sciences, Inc. | Methods for treating hcv |
CN103848877B (zh) * | 2013-12-16 | 2016-08-24 | 安徽贝克联合制药有限公司 | 核苷环磷酸酯化合物及其制备方法和其应用 |
CN103804446A (zh) * | 2014-02-27 | 2014-05-21 | 苏州东南药业股份有限公司 | 一种3,5-二苯甲酰基-2-去氧-2-氟-2甲基-D-核糖-γ-内酯的制备方法 |
-
2014
- 2014-08-08 CN CN201410391177.9A patent/CN104130302B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN104130302A (zh) | 2014-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104130302B (zh) | 一种核苷药物的晶型及其制备方法 | |
US9884869B2 (en) | Ibrutinib solid forms and production process therefor | |
CN104892486B (zh) | 阿普斯特的晶型b+及其制备方法 | |
WO2019052133A1 (zh) | Gsk1278863的晶型及其制备方法和制药用途 | |
CN108884080A (zh) | 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用 | |
Furuta et al. | Physicochemical and crystal structure analysis of pranlukast pseudo-polymorphs II: solvate and cocrystal | |
CN105732751A (zh) | 索非布韦新晶体 | |
JP6404461B2 (ja) | ロバプラチン結晶体、調製方法及び薬物応用 | |
Gong et al. | Structure, characterization, solubility and stability of podophyllotoxin polymorphs | |
CN105985394B (zh) | 一种索非布韦新晶型及其制备方法 | |
WO2022170864A1 (zh) | Belumosudil甲磺酸盐的晶型及其制备方法和用途 | |
CN110312705B (zh) | Gft-505的晶型及其制备方法和用途 | |
CN105859818A (zh) | 一种奥贝胆酸α晶型及其制备方法、药物组合物和用途 | |
CN103880906B (zh) | 一种丁酸氢化可的松半水合物 | |
WO2023016319A1 (zh) | Lanifibranor的晶型及其制备方法和用途 | |
CN114644642B (zh) | 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物 | |
CN103709156B (zh) | 一种达沙替尼多晶型药物及其制备方法 | |
Yang et al. | Thermodynamic stability analysis of m-nisoldipine polymorphs | |
WO2021104021A1 (zh) | Tropifexor的新晶型及其制备方法 | |
CN104379557A (zh) | 阿戈美拉汀晶型i的制备方法 | |
WO2021104022A1 (zh) | Tropifexor的新晶型及其制备方法 | |
CN114258395A (zh) | 一种酯化合物的晶型及其制备方法 | |
CN105384724A (zh) | 一种氟代物的晶型及其制备方法 | |
CN108084237A (zh) | 索非布韦的一水合物及其制备方法 | |
WO2019149262A1 (zh) | Sb-939的晶型及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: RUYUAN HEC PHARM CO., LTD. Free format text: FORMER OWNER: GUANGDONG DONGYANGGUANG PHARMACEUTICAL CO., LTD. Effective date: 20150515 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150515 Address after: Dam zone 512721 Guangdong city of Shaoguan province Ruyuan Yao Autonomous County town of dragon bay Hou Gong Du milk Applicant after: RUYUAN HEC PHARM Co.,Ltd. Address before: 523808 Guangdong city of Dongguan province Hubei Songshan Industrial Park Industrial Road No. 1 Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Crystal form of a nucleoside drug and its preparation method Effective date of registration: 20201215 Granted publication date: 20170215 Pledgee: Guangdong Ruyuan Rural Commercial Bank Co.,Ltd. Pledgor: RUYUAN HEC PHARM Co.,Ltd. Registration number: Y2020990001445 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230310 Granted publication date: 20170215 Pledgee: Guangdong Ruyuan Rural Commercial Bank Co.,Ltd. Pledgor: RUYUAN HEC PHARM Co.,Ltd. Registration number: Y2020990001445 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The crystal form of a nucleoside drug and its preparation method Effective date of registration: 20230317 Granted publication date: 20170215 Pledgee: Guangdong Shixing Rural Commercial Bank Co.,Ltd. Pledgor: RUYUAN HEC PHARM Co.,Ltd. Registration number: Y2023980035185 |